@entity16396 (Ro 17-2301; XXXX ) compared with @entity801 for treatment of complicated urinary tract infections.

@entity1 @entity801 @entity1494 @entity3527 @entity294 @entity16396
Carumonam and @entity801 were compared in a prospective, randomized study of 52 @entity1 with complicated urinary tract infections. @entity1 were treated with either carumonam (1 g every 8 h) or @entity801 (1 mg/kg every 8 h). The mean duration of therapy (carumonam, 8.5 days; @entity801 , 8.5 days) was similar for both groups. A total of 45% of @entity1 treated with @entity16396 and 48% of those receiving @entity801 were cured, as defined by a negative culture 1 to 2 weeks after therapy. After 4 to 6 weeks, the figures were 27% for carumonam and 38% for @entity801 . In the carumonam group, there were 6 relapses and 11 reinfections. In the @entity801 group, there were eight relapses and five reinfections. Adverse effects in the carumonam group were limited to @entity3527 at the intravenous infusion site in two @entity1 ; another @entity1 developed @entity294 . Nephrotoxicity was documented in two @entity1 in the @entity801 treatment group (9%), and another @entity1 developed minor liver function disturbances. Three @entity1 with @entity801 -resistant carumonam-susceptible isolates were treated with carumonam, and two were cured. Urinary colonization with group D streptococci occurred in 7 of 27 (26%) carumonam-treated @entity1 compared with 7 of 19 (37%) @entity801 -treated @entity1 ; no one required treatment. A significant correlation was found between colonization with group D streptococci and @entity1494 (P less than 0.007). It is concluded that the use of the carumonam is as effective as the @entity801 regimen in the treatment of complicated urinary tract infections.
